About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Nashville | 288 Studies

Clinical Trials MelanomaNashville

Melanoma Clinical Trials in Nashville

Find 288 clinical trials for melanoma near Nashville, Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 21-40 of 288 trials

CompletedA Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsThe main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with…NCT02791334·Nashville, Tennessee and 13 others CompletedTrametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 MutationsThis phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other…NCT02296112·Washington D.C., District of Columbia and 3 others TerminatedA Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesA Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in…NCT03829501·Duarte, California and 21 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedRTX-224 Monotherapy in Patients With Solid TumorsThis is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid…NCT05219578·Scottsdale, Arizona and 4 others

TerminatedStudy to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceThe main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV…NCT04410445·Scottsdale, Arizona and 211 others

RecruitingPhase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabProtocol Title: Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003…NCT07751042·Scottsdale, Arizona and 3 others

CompletedA Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with…NCT01006980·Birmingham, Alabama and 110 others

CompletedStudy of XL281 in Adults With Solid TumorsThe purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it…NCT00451880·Scottsdale, Arizona and 5 others

Active not recruitingSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCThis is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single…NCT04140526·Springdale, Arkansas and 36 others

Active not recruitingA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsThis is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR…NCT05653882·Duarte, California and 19 others

CompletedA Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal MelanomaIMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM).NCT02570308·La Jolla, California and 25 others

RecruitingProject: Every Child for Younger Patients With CancerThis study gathers health information for the Project: Every Child for younger patients with cancer.NCT02402244·Birmingham, Alabama and 278 others

TerminatedThis SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung…NCT05061940·Scottsdale, Arizona and 2 others

CompletedStudy to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced CancerThis is a Phase 1, open-label, multi-center, first time in human study of AMP-224 in adult patients with cancer that is not responding to standard therapy.NCT01352884·Detroit, Michigan and 3 others

CompletedA Study of BIND-014 Given to Patients With Advanced or Metastatic CancerThe goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.NCT01300533·Scottsdale, Arizona and 5 others

TerminatedA Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic MelanomaTo evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.NCT00627419·Tuscon, Arizona and 16 others

TerminatedA FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementFirst-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF…NCT04543188·Duarte, California and 44 others

TerminatedDabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By SurgeryThis phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be…NCT01701037·Nashville, Tennessee

CompletedA Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic MelanomaThe goal of the Phase 1 study was to find the recommended Phase 2 dose of the study drug IMO-2125 (tilsotolimod) that can be given in combination with ipilimumab (ipi) or…NCT02644967·Tucson, Arizona and 9 others

TerminatedTissue Procurement Substudy for Participants in Study CP-MGA271-01The purpose of this study is to gain a better understanding about how the study drug MGA271 works. No test drug will be given in this study.NCT01918930·Los Angeles, California and 6 others

PreviousPage 2 of 15Next

Other Conditions in Nashville

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma